<u>ORIGINAL</u>

Effect of ursodeoxycholic acid on azoxymethane-induced aberrant crypt foci formation in rat colon : *in vitro* potential role of intracellular Ca²⁺

Mohammed Abdul Momen¹, Yasumasa Monden¹, Hitoshi Houchi² and Atsushi Umemoto¹

¹Second Department of Surgery, and ²Division of Pharmacy, University Hospital, The University of Tokushima School of Medicine, Tokushima, Japan

Abstract: The studies were conducted to examine the precise nature of the suppressive effect of ursodeoxycholic acid (UDCA) on colonic aberrant crypt foci (ACF) formation. Fischer 344 rats were treated with a single dose of azoxymethane (AOM) (20 mg/kg, s.c.) and fed basal diet (MF) supplemented with UDCA (0.4%) during an initiation or a post-initiation stage. ACF were enumerated at the 2nd, 5th and 8th weeks after AOM administration (15-18 rats/group). The number of ACF in the UDCA treated group was decreased significantly in the initiation and post-initiation stages at the 2nd (*P*<0.01, *P*<0.0001) and 8th weeks (*P*<0.001, *P*<0.0001), respectively, compared with untreated controls. In the time-course experiments, the effect of continuous feeding of UDCA (0.4%) on ACF formation was evaluated. ACF number was decreased significantly (P<0.005) until the 16th week. UDCA showed a significant dose-dependent suppression of ACF number from a range of 0.1-0.4% UDCA. To approach the subcellular mechanisms of the effect of bile acids, the intracellular free Ca²⁺ concentration ([Ca²⁺]_i) of bile acid-treated rat colonic cancer cells (ACL-15) was examined. DCA and CDCA, which are promotive on ACF formation, induced a rapid increase in [Ca²⁺]_i, while UDCA and CA, which are suppressive or non-effective on ACF formation, did not. These findings suggest that the promotive effect of bile acids may involve intracellular Ca²⁺ signaling. J. Med. Invest. 49:67-73, 2002

Keywords : ursodeoxycholic acid, aberrant crypt foci, colon cancer, bile acid, intracellular Ca^{2+}

INTRODUCTION

The incidence of colorectal cancer in Japan has increased over the past four decades, and it was suggested that this increase is linked to increased consumption of Western foods characterized by high-fat and less fiber diets. Such dietary habits are known to be correlated with high fecal concentrations of bile acids. In agreement with this, epidemiological studies showed that fecal concentrations of bile acids were high in patients with colon cancer as well as in people from countries with a high incidence of colon cancer (1, 2). Thus, all these findings suggest that a strong relation between fecal bile acids and human colon carcinogenesis. Bile acids have also been studied extensively in animal models of colon cancer (3-5). In our previous studies, the effects of human bile acids on azoxymethane (AOM)-induced aberrant crypt foci (ACF), which is a good surrogate marker for colon carcinogenesis, were investigated in the rat

Received for publication January 5, 2002; accepted January 31, 2002.

Address correspondence and reprint requests to Atsushi Umemoto, Second Department of Surgery, The University of Tokushima School of Medicine, Kuramoto-cho, Tokushima 770-8503, Japan and Fax: +81-88-633-7144.

colon (6, 7). In these studies using dietary intake and intracolonic administration of bile acids, ursodeoxycholic acid (UDCA) showed a significant suppressive effect on ACF formation, whereas other bile acids, i.e. cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA) and lithocholic acid (LCA), showed either promotive effects or no effect on the colonic mucosa. The preventive effect of UDCA on colonic tumor formation was also demonstrated in rats (5). Although controversies continue with respect to finding a correlation between the ACF parameters and tumor outcome, as a precursor lesion of the colon cancer (8, 9), it has been established that ACF is a good biomarker to assess the effects of colon carcinogens as well as chemopreventive agents (10, 11). UDCA may be one of the hopeful chemopreventive agents for high-risk groups for colon cancer. In the present study, the effects of UDCA in different stages of colon carcinogenesis by AOM treatment were examined in Fischer 344 (F344) rat colon and the time-course and dose-response of the effects of UDCA on ACF formation were also examined.

Although, the bile acids are greatly involved in the development of colon tumors and ACF, the exact mechanism of the bile acids action remains unclear. Increasing evidence suggests that colonic malignant transformation involves various mutations activating proto-oncogenes such as K-ras (12), inactivating tumor suppressor genes such as p53 and APC (13), and inactivating genes involved in DNA mismatch repair. On the other hand, epigenetic changes in signal transduction elements, such as protein kinase C (PKC) may also be involved in multistage processes of colon carcinogenesis (14, 15). Bile acids, which have various effects on colonic ACF formation, are also known activators of PKC that have been implicated in the development of colonic carcinoma (16). Since PKC is activated by intracellular calcium ions, it is possible to have an association between the effect of bile acids and their intracellular calcium induction. It was also reported that calcium ions (Ca^{2+}) are a versatile mediator of many cellular biological processes, including cell proliferation (17). The free Ca²⁺ acts as a proliferative signal for many normal cells (18). Cytoplasmic calcium is also a pluripotent regulator of cell function including the cell cycle and apoptosis (19, 20). Thus, the agents that affect the intracellular calcium level, could be considered as important substances for cell functions, and we hypothesized that bile acid activity on cellular proliferation leading to ACF formation may be in part through the alteration of the intracellular calcium level. Therefore, we aimed to assess the intracellular Ca²⁺ induction in rat a colon cancer cell line (ACL-15) by bile acids, which are either promotive or suppressive/ ineffective in colonic ACF formation in rats.

MATERIALS AND METHODS

Chemicals

CA, CDCA and DCA were purchased from Sigma Chemical Co. (St. Louis, MO). UDCA was from Mitsubishi-Tokyo Pharmaceutical Co. Ltd. (Tokyo, Japan). All the bile acids were sodium salt forms and these were at least 97-99% pure according to the manufacturer's indications. AOM was purchased from Sigma Chemicals Co. (St. Louis, MO). Fura-2-AM[™] was obtained from Dojindo Laboratories (Kumamoto, Japan). Micro-cover glass (13 mm in diameter) was obtained from Matsunami Glass Ind. Ltd. (Osaka, Japan).

Animals

Six-week-old, male, F344 rats were purchased from SLC Co. (Hamamatsu, Japan) and housed in polycarbonate cages with wood chips in a specific pathogen-free laboratory of our animal facilities, three rats/cage. They were kept under constant conditions of temperature (22 ± 2) and humidity ($55 \pm 5\%$) with a 13 hr light/11 hr dark cycle. All the rats were provided with laboratory chow basal diet (MF) (Oriental Yeast Co. Ltd., Tokyo, Japan) unless specified and the beds were changed twice a week. The arrival weight and food consumption of the animals were recorded.

Study design

Study-1(Initiation and post-initiation)

Male F344 rats (6 weeks old) were treated with a single dose of AOM (20 mg/kg, 10 mg/ml in sterile saline) subcutaneously. Rats were allocated to one of 3 experimental groups, the control and two UDCA groups (initiation and post-initiation, 15-18 rats/group). In the initiation group, the rats were fed MF (Oriental Yeast, Co., Ltd., Tokyo, Japan) supplemented with the UDCA (0.4%) *ad libitum* from four days before to three days after the AOM injection (for 1 week), and thereafter the rats were fed MF alone (Fig. 1 A). In the post-initiation group, the MF was changed to a UDCA-supplemented diet (0.4%) one week after AOM injection (Fig. 1B). The control group was fed the MF during the entire experimental period (Fig. 1C). Rats (n=5-7) were sacrificed at the 2nd, 5th and 8th weeks.

The isolated colons were collected and washed with 0.9% NaCl water solution. The lumen of the colon was filled with 10% phosphate-buffered formalin (pH 7.4) for 3 min. These were incised in a longitudinal direction and fixed flat between two pieces of filter paper in the buffered formalin. The colons were stained with 0.2% methylene blue (Sigma Chemical Co., St. Louis, MO) and the number of ACF along the colon was counted by their position in every 2 cm under light microscope (21) from the anus to proximal

Study-2 (Time-course)

colon.

In this study, the rats (6 weeks old) were treated with AOM as Study-1. One week later, the rats were divided into two groups and were fed *ad libitum* the MF diet supplemented with UDCA (0.4%) or MF alone, until the end of the experiment (Fig. 1D). Rats (n=4-5) were sacrificed at the 2nd, 4th, 8th, 16th and 32nd weeks to count the colonic ACF.

Study-3 (Dose-response)

After treatment with AOM as a single dose and MF feeding for 1 week, the rats were divided into five groups (6 rats/group). From the beginning of the second week rats were fed *ad libitum* the MF supplemented with different concentrations of UDCA (0.05%, 0.1%, 0.2% and 0.4%) or MF alone (Fig. 1E).

At the end of 5th week the rats were sacrificed to evaluate the colonic ACF.

Statistical analyses in all studies were carried out using analysis of variance (ANOVA), and *P*<0.05 was considered significant.

Cell culture

The rat colon cancer cell line (ACL-15 cells) was obtained from Riken Cell Bank (Tsukuba, Japan). ACL-15 cells were grown in a 5% CO₂-95% air humidified atmosphere at 37 and maintained for 3-5 days as monolayer cultures in Dulbecco's modified Eagle's minimum essential medium (DMEM; Nissui, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, penicillin (100 units/ml), streptomycin (100 μ g/ml) and gentamycin (40 μ g/ml). The cells were plated on 13 mm-diameter round cover glasses in 35-mm culture dishes at a density of 1 × 10⁶ cells/dish.

Measurement of intracellular free $[Ca^{2+}]_i$

The cells were incubated at 37 for 30 min in 1 ml of calcium containing phosphate-buffered saline PBS(+)/ 4 μ M fura-2/acetoxy methyl ester, a fluorescent Ca²⁺ indicator. Then, the cells on cover glasses were transferred to a small incubation bath (approx. 0.5 ml) that was continuously rinsed with PBS(+) on the platform of a microscope. Together with the onset of



Fig. 1 Study protocols. (A) Study-1 (initiation), (B) Study-1 (post-initiation), (C) Study-1 (control). Rats (5-7 rats/group in each time point) were sacrificed at the 2nd, 5th and 8th weeks. (D) Study-2 (time-course, 4-5 rats/group at each time point were sacrificed). (E) Study-3 (dose-response, 6 rats/dose-group). AOM ; azoxymethane, UDCA ; ursodeoxycholic acid, MF ; basal diet.

the intracellular free Ca²⁺ concentration ($[Ca^{2+}]_i$) measurement, PBS(+) rinsing the cells was immediately replaced by 1 mM bile acid-containing PBS(+). Fluorescence of the cells was measured using a fluorescence spectromicroscope (excitation, 340/380 nm; emission, 510 nm). About ten cells that showed apparently normal morphological features, that were isolated from surrounding cells were selected for measurement in each bile acid case. The $[Ca^{2+}]_i$ was calculated using the previously reported equation (22).

RESULTS

Effect of UDCA on ACF formation

In Study-1, the UDCA (0.4%) supplemented diet decreased the ACF number both during the initiation and post-initiation stages (Fig. 2A). After two weeks of UDCA treatment, the ACF numbers in the initiation and post-initiation groups decreased significantly to 83.8% and 64.7% of the control group (average : 56.8 ACF/colon), respectively (P<0.01, P< 0.0001). At the 5th week of enumeration, the numbers in the initiation and post-initiation groups decreased to 82.3% and 87.0% of the control (average :

74.4 ACF/colon), respectively, but these suppressions were not significant. At the 8th week, the ACF numbers in the initiation and post-initiation groups decreased significantly to 74.6% and 65.0% of the controls (average : 92.0 ACF/colon), respectively (P < 0.001, P < 0.0001). At the end of 8th week, the total numbers of aberrant crypts (AC) in the initiation and post-initiation groups showed decreasing tendencies by 77.8% and 66.2% of the control (average : 283.0 AC/colon), respectively, but they were not significantly different from controls.

In the time-course study (Study-2), the numbers of ACF in the UDCA supplemented diet group were 46.0%, 70.7%, 85.1%, 66.4% and 82.5% of controls in the 2nd, 4th, 8th, 16th and 32nd weeks, respectively (Fig. 2B). The numbers of ACF decreased significantly in the UDCA supplemented diet group at the 2nd (*P*<0.001), 4th (*P*<0.005) and 16th weeks (*P*<0.005), but at the 32nd week, the ACF number was not significantly decreased. The maximum suppressive effect of UDCA was observed at the 2nd week (46.0% of controls), whereas it was minimum (82% of controls) at the 32nd week, the end of the experiment.

In the dose-response study (Study-3), dietary administration of UDCA decreased the number of ACF in a dose-dependent manner. The suppressive effect of UDCA on ACF formation was significant in UDCA



Fig. 2. Effect of ursodeoxycholic acid (UDCA) on azoxymethane (AOM)-induced aberrant crypt foci (ACF) formation in the rat colon.

(A) Study-1 (, control; , initiation; , post-initiation). UDCA (0.4%) decreased the number of ACF both in the initiation and post-initiation stages of colon carcinogenesis.
(B) Study-2 (time-course) (, control;

, UDCA). (C) Study-3 (dose-response)

of 0.1% (P <0.05), 0.2% (P <0.01) and 0.4% (P <0.005). UDCA of 0.05% did not decrease the numbers of ACF significantly (Fig. 2C).

Effect of bile acids on $[Ca^{2+}]_i$ *of* ACL-15 *cells*

Measurement of intracellular Ca²⁺ by fluorescence microscopy revealed that CDCA and DCA induced a rapid increase in $[Ca^{2+}]_i$ even when extracellular Ca²⁺ was abolished (Fig. 3C-D). CDCA and DCA (1 mM) increased $[Ca^{2+}]_i$ to a peak of approximately 120 nM and 100 nM, respectively, followed by its gradually decrease to a steady level. In contrast, UDCA and CA did not induce an increase in $[Ca^{2+}]_i$ (Fig. 3A-B).

DISCUSSION

In our previous studies, we found that UDCA suppressed the carcinogen-induced colonic ACF formation in rats (6, 7). In the present study, we also observed an ACF-suppressive effect of UDCA. To observe the ACF suppressive effect of UDCA in detail, we investigated the effect of UDCA on ACF using different protocols. In study-1A of the present study, it was shown that UDCA could decrease the AOM-induced ACF number during the initiation as well as during the post-initiation, suggesting that UDCA affects both stages of colon carcinogenesis. In the time-course study that examined the long-term effect of UDCA, we found that UDCA continued to significantly suppress the ACF number compared with controls until the 16th week of the experiment (70.8 vs. 106.6), at the 32nd week the ACF number of UDCA and MF fed groups (60.0 vs. 72.7 ACF/colon) did not differ so much as the early period of the experiment. In the present dose-response study of UDCA we observed that the MF diet supplemented with 0.05% and 0.1% of UDCA suppressed the ACF number gradually, but unexpectedly this suppressive effect of UDCA did not increase so markedly at doses higher than 0.1%. The exact cause(s) of these variable effects of UDCA remains to be clarified. However, it was reported that orally supplemented bile acids are frequently converted to other bile acids by the enterohepatic circulation as well as by enzymatic action of gut flora (7, 23, 24). In our previous study with dietary administration of UDCA and other bile acids, the fecal bile acids analysis revealed that similar to other bile acids, UDCA was also converted to muricholic acid (50.8%), LCA (10.2%), hydodeoxycholic acid (8.7%), DCA (4.1%), CDCA (0.4%) and others (7). These converted acids are known as ACF promoting bile acids and this conversion was suggested to be changed in terms of quality and quantity in long-term administration. This may be one of the causes for UDCA not to continue its ACF suppressive effect beyond a certain dose and time. Moreover, rat colonic mucosal cells may change



Fig. 3. Effect of bile acids on $[Ca^{2+}]_i$ in ACL-15 cells. (A) UDCA, (B) CA, (C) CDCA, (D) DCA. Time 0 indicates when the bile acid (1 mM) contacted the cells. Each value indicates the "mean \pm SD" of about ten cells measured.

their response to UDCA after long-term administration.

The mechanism(s) involved in tumor promotion by bile acids remains unclear. Similarly, the mechanisms involved in the anticarcinogenic effects of UDCA on experimental colonic cancer also remain to be clarified. Alterations in protein kinase C (PKC) are involved in colonic malignant transformation in humans (14) and in animals (15). PKC constitutes a gene family of serine/threonine protein kinases that play central roles in transmembrane signaling events, and are involved in diverse biological processes, including cellular proliferation and differentiation (25). Bile acids, which are known as activators of PKC (16), can also stimulate the membrane phospholipase C that converts the phosphatidylinositol biphosphate to inositol triphosphate (IP₃) and diacylglycerol (DAG). IP₃ acts on endoplasmic reticulum and this released calcium ions into the cytoplasm. These calcium ions in addition to the DAG, ultimately activate the PKC for further activities. Therefore, bile acids can activate the PKC via the induction of intracellular calcium ions. In the present study, CDCA and DCA which were previously reported to increase the number of ACF in the rat colon (6, 7), induced a rapid increase in the [Ca²⁺]_i in ACL-15 cells. Thus, the ACF promotive effect of CDCA and DCA in animal model studies agrees with the present in vitro finding of their calcium ion induction. From this result we can say that the effect of CDCA and DCA may be, in part, related to the increase in [Ca²⁺]_i. However, CA, which showed no effect (7) or suppressive effect (26) on ACF formation, and UDCA, which suppressed the ACF number (6, 7), did not show any effect on $[Ca^{2+}]_i$. Although the ineffective nature of the CA on colonic ACF formation is consistent with its effect of unchanged [Ca²⁺]_i, the suppressive effect of CA and UDCA on ACF formation is not correlated with their $[Ca^{2+}]_i$ induction. Other mechanism(s) in this suppression process may be involved and remain to be clarified.

In conclusion, regardless of the exact mechanism(s) of bile acids to produce colonic ACF, the present findings demonstrated that the ACF promotive activity of bile acids in rat colonic mucosa may be through the involvement of PKC that is activated partly by intracellular calcium ions. Therefore, it is suggested that there is a possible relation between the intracellular calcium ion induction by bile acids and the effects of bile acids on ACF formation.

ACKNOWLEDGEMENTS

This study was supported by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare, Japan. A doctoral fellowship to Md. Abdul Momen from the Ministry of Education, Science, Sports and Culture of Japan is gratefully acknowledged.

REFERENCES

- Reddy BS, Wynder EL : Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 39 : 2533-2539, 1977
- 2. Spigelman AD, Owen RW, Hill MJ, Phillips RK : Biliary bile acid profiles in familial adenomatous polyposis. Br J Surg 78 : 321-325, 1991
- Narisawa T, Magadia NE, Weisburger JH, Wynder EL : Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 53 : 1093-1097, 1974
- Narahara H, Tatsuta M, Iishi H, Baba M, Uedo N, Sakai N, Yano H, Ishiguro S : K-ras point mutation is associated with enhancement by deoxycholic acid of colon carcinogenesis induced by azoxymethane, but not with its attenuation by all-trans-retinoic acid. Int J Cancer 88 : 157-161, 2000
- Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA : Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54 : 5071-5074, 1994
- Seraj MJ, Umemoto A, Kajikawa A, Mimura S, Kinouchi T, Ohnishi Y, Monden Y : Effects of dietary bile acids on formation of azoxymethane-induced aberrant crypt foci in F344 rats. Cancer Lett 115 : 97-103, 1997
- Lin C, Umemoto A, Jabed MS, Mimura S, Monden Y : Effect of bile acids on formation of azoxymethane-induced aberrant crypt foci in colostomized F344 rat co-Ion. Cancer Lett 169 : 121-126, 2001
- Hardman WE, Cameron IL, Heitman DW, Contreras E : Demonstration of the need for end point validation of putative biomarkers : failure of aberrant crypt foci to predict colon cancer incidence. Cancer Res 51 : 6388-6392, 1991
- 9. Thorup I, Meyer O, Kristiansen E : Influence of a dietary fiber on development of dimethylhydrazine-induced

aberrant crypt foci and colon tumor incidence in Wistar rats. Nutr Cancer 21 : 177-182, 1994

- Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE : Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15 : 1049-1054, 1994
- Wargovich MJ, Chen C-D, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ: Aberrant crypts as a biomarker for colon cancer : evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomark Prev 5 : 355-360, 1996
- Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL : K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 85 : 2004-2007, 1993
- 13. Vogelstein B, Kinzler KW : The multistep nature of cancer. Trends Genet 9 (4) : 138-141, 1993
- Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A : Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 51 : 205-210, 1991
- Craven PA, DeRubertis FR : Alterations in protein kinase C in 1,2-dimethylhydrazine induced colonic carcinogenesis. Cancer Res 52 : 2216-2221, 1992
- Pongracz J, Clark P, Neoptolemos JP, Lord JM : Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 61 : 35-39, 1995
- 17. Metcalfe JC, Moore JP, Smith GA, Hesketh TR : Calcium and cell proliferation. Br Med Bull 42 :

405-412, 1986

- Hickie RA, Wei JW, Blyth LM, Wong DY, Klaassen DJ : Cations and calmodulin in normal and neoplastic cell growth regulation. Can J Biochem Cell Biol 61 : 934-941, 1983
- Santella L, Kyozuka K, De Riso L, Carafoli E : Calcium, protease action, and the regulation of the cell cycle. Cell Calcium 23 : 123-130, 1998
- 20. Nicotera P, Orrenius S : The role of calcium in apoptosis. Cell Calcium 23 : 173-180, 1998
- 21. Bird RP : Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen:preliminary findings. Cancer Lett 37 : 147-151, 1987
- Grynkiewicz G, Poenie M, Tsien RY : A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem 260 : 3440-3450, 1985
- 23. Hill MJ : The enterohepatic circulation. In : Bustos-Fernandez L eds. Colon, Structure and Function, Plenum, New York, 1983, pp. 233-252
- Sarwal AN, Cohen BI, Raicht RF, Takahashi M, Fazzini E : Effects of dietary administration of chenodeoxycholic acid on N-methyl-N-nitrosourea-induced colon cancer in rats. Biochim Biophys Acta 574 : 423-432, 1979
- Nishizuka Y : Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (Washington DC) 258 : 607-614, 1992
- 26. Magnuson BA, Bird RP : Reduction of aberrant crypt foci induced in rat colon with azoxymethane or methylnitrosourea by feeding cholic acid. Cancer Lett 68 : 15-23, 1993